“出海”是中国近几年 生物医药 产业最热的话题之一。与这个话题相关联的,往往是一笔笔刷新纪录的交易金额,跨国巨头的青睐和国内 创新药 企新秀的强强联合。然而,在最近一笔横空出世的创新药“天价交易”背后,主角之一却是一家诞生于1993年的老牌药企—— 三生制药 。“宇宙大厂”辉瑞以12.5亿美元(约90亿元人民币)不可退还且不可抵扣的首付款将三生制药附属公司 三生国健 旗下抗癌药SSGJ-707非...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.